The Hidden Costs of Medical Device Development
When people think about the cost of developing a medical device, they often think first about engineering.
They think about prototype builds, design resources, testing, regulatory consulting, clinical studies, equipment, and manufacturing.
Those are all real costs.
But one of the most underestimated costs in medical device development is not engineering itself.
It is iteration.
Iteration is an essential part of creating a safe, effective, usable, and manufacturable medical device. Every successful product goes through change. The challenge is not avoiding iteration entirely.
The challenge is avoiding late-stage iteration that could have been prevented through better planning, stronger cross-functional alignment, and earlier lifecycle thinking.
A small design decision made early in development can create major consequences later if it affects manufacturing, regulatory strategy, suppliers, clinical use, testing, or commercialization.
Why Iteration Becomes Expensive
In early concept development, changes are usually expected.
A team may adjust a handle shape, change a component material, update device geometry, refine a mechanism, or test multiple prototype configurations. At this stage, change is often relatively fast and inexpensive.
As a medical device moves further into development, however, each change can affect more of the program.
A design update may trigger changes to:
Supplier specifications
Tooling or fixtures
Manufacturing processes
Test methods
Inspection criteria
Product requirements
Risk-management documentation
Verification plans
Packaging and sterilization strategy
Clinical-study materials
Regulatory documentation
Product cost and commercialization timeline
The later the change occurs, the more connected work must be revisited.
That is why a seemingly small design modification can create a large financial and schedule impact.
The Cascade Effect of Late Design Changes
Consider a simple example.
A team identifies a small component issue late in development. The part may need to change because of performance, manufacturability, usability, supplier capability, or quality concerns.
At first, the update may appear straightforward.
But the change could require:
New component drawings and specifications
Supplier requalification or a new supplier
Tooling changes or new tooling
Updated assembly instructions
Updated inspection methods
Additional process development
New verification testing
Risk-file updates
Traceability updates
Packaging compatibility review
Sterilization impact assessment
Updated regulatory documentation
Delays to a planned clinical or commercial milestone
The direct cost of changing the part may be modest.
The total cost of the ripple effect may not be.
This is why medical device development requires teams to think beyond the immediate technical solution.
What Startups Commonly Underestimate
Most startups plan for major development activities.
They budget for engineering, prototypes, regulatory strategy, clinical work, and manufacturing support.
What they may underestimate is the cost of decisions that are made without considering the full product lifecycle.
Common examples include:
Designing for Prototype Performance Only
A prototype may work well in a development environment but be difficult to assemble, inspect, package, sterilize, or manufacture at commercial volume.
When manufacturability is not considered early, the product may require redesign during manufacturing transfer.
Engaging Suppliers Too Late
A component may look practical on paper but create problems related to availability, lead time, minimum order quantity, material consistency, tooling requirements, or manufacturing capability.
Early supplier input can identify risks before the design becomes difficult to change.
Delaying Automation Thinking
Not every device needs automation at the prototype stage.
However, part geometry, tolerances, material behavior, assembly sequence, and inspection requirements can all affect whether future automation is practical or expensive.
Waiting until production demand increases may limit options and require costly redesign.
Treating Regulatory Strategy as a Final Step
Regulatory planning should help guide development decisions.
When intended use, requirements, risk controls, testing needs, and clinical evidence strategy are considered too late, teams may need to repeat work or generate additional evidence after development has already progressed.
Underestimating Manufacturing Transfer
Manufacturing transfer is not simply handing a design to a contract manufacturer or production team.
It is a structured transition that requires process definition, quality controls, supplier alignment, inspection strategy, documentation, training, validation planning, and commercial readiness.
When transfer planning begins too late, delays become more likely.
Designing with the Full Lifecycle in Mind
The companies that move efficiently toward commercialization are not necessarily the ones that avoid changes.
They are the ones that make earlier decisions with a broader understanding of what those decisions will affect.
Designing with the full lifecycle in mind means considering:
Clinical use and workflow
User needs and product requirements
Product performance and safety
Risk management
Regulatory pathway and evidence needs
Component sourcing and supplier capability
Assembly methods and process variation
Inspection and quality controls
Packaging and sterilization
Manufacturing cost and capacity
Automation readiness
Commercial production and future scale-up
This approach helps teams preserve flexibility while the product is still evolving.
It also helps prevent avoidable changes after key decisions have already been made.
The Role of Cross-Functional Alignment
No single function can manage these risks alone.
Engineering may understand device performance. Manufacturing may understand process capability. Quality and regulatory teams may understand documentation and evidence requirements. Supply-chain teams may understand supplier risk. Clinicians may identify workflow challenges that affect usability or design.
The most effective development teams bring these perspectives together early.
That does not mean slowing down every decision with unnecessary reviews.
It means involving the right stakeholders at the points where their input can prevent expensive rework.
A strong cross-functional development process often includes:
Clear user needs and product requirements
Early manufacturing and supplier input
Design-for-manufacturability reviews
Risk-management activities
Regulatory pathway planning
Clinical and usability feedback
Verification and validation strategy
Manufacturing transfer planning
Defined ownership, milestones, and decision points
The goal is to identify major downstream impacts while change is still manageable.
Iteration Is Not the Problem
Iteration is necessary.
The best medical devices are improved through engineering learning, clinician feedback, feasibility work, testing, preclinical studies, manufacturing development, and quality review.
The issue is not that a product changes.
The issue is when the product changes without a clear understanding of the downstream consequences.
The right kind of iteration is intentional.
It is driven by meaningful learning. It is connected to user needs, product requirements, risk reduction, manufacturing strategy, and commercialization goals.
That type of iteration makes the product stronger.
Unplanned late-stage iteration can make the program slower, more expensive, and more difficult to manage.
How Early Planning Protects Time and Capital
Early lifecycle planning can help medical device companies:
Reduce redesign risk
Improve supplier and manufacturing readiness
Avoid unnecessary tooling changes
Build a stronger regulatory and testing strategy
Improve product quality and process repeatability
Support future automation decisions
Protect clinical and commercialization timelines
Reduce cost during manufacturing transfer
Improve visibility for founders, investors, and leadership teams
The earlier these conversations occur, the more options a team has.
A small design change may still be necessary—but it can be made at the right point in the program, with the right information, before it creates a larger cascade of work.
Innovation Wins When Strategy Is Connected
The strongest MedTech companies do not treat engineering, regulatory planning, clinical work, and manufacturing as separate phases that happen one after another.
They treat them as connected parts of the same commercialization journey.
That is how teams reduce unnecessary rework, maintain momentum, and make more confident decisions as their technology matures.
At Birch Design, we help medical device innovators bridge the gap between engineering innovation and scalable production. From product development strategy and fractional program leadership to manufacturing readiness, automation planning, supplier coordination, and commercialization support, Birch Design helps teams build with the full lifecycle in mind.
Building a medical device and trying to reduce development risk before it becomes expensive? Birch Design helps teams create a clearer path from concept through scalable production and commercialization.